Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, August 13th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Free Report) last released its earnings results on Thursday, May 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74). Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. The company had revenue of $28.43 million during the quarter, compared to analyst estimates of $35.78 million. On average, analysts expect Calliditas Therapeutics AB (publ) to post $-1 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Calliditas Therapeutics AB (publ) Stock Performance
Shares of NASDAQ CALT opened at $39.61 on Monday. The company has a debt-to-equity ratio of 8.46, a quick ratio of 2.62 and a current ratio of 2.69. The stock has a 50 day moving average price of $39.03 and a 200 day moving average price of $27.87. The stock has a market capitalization of $1.18 billion, a PE ratio of -21.41 and a beta of 1.77. Calliditas Therapeutics AB has a 52 week low of $15.25 and a 52 week high of $41.90.
Analysts Set New Price Targets
Check Out Our Latest Research Report on Calliditas Therapeutics AB (publ)
About Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.
Read More
- Five stocks we like better than Calliditas Therapeutics AB (publ)
- What is the S&P 500 and How It is Distinct from Other Indexes
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- How to Calculate Inflation Rate
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.